Clinical study of tazobactam/piperacillin in obstetrics and gynecological infections
Chimura, T.; Hirayama, T.
Japanese Journal of Antibiotics 49(8): 808-812
1996
ISSN/ISBN: 0368-2781 PMID: 9053535 Document Number: 460474
A clinical study was carried out to investigate clinical efficacy and safety of tazobactam/piperacillin (TAZ/PIPC), a newly developed antibiotic agent for injections. The obtained results are as follows: 1. In 10 patients with obstetrics and gynecological infections (7 patients with endometrial infections, one patient with pelvic peritonitis, one patient with ovarian abscess and one patient with BARTHOLIN's abscess) intravenous drip infusion of TAZ/PIPC, 5.0 g/day, was administered for 5 to 10 days. The total doses were 25 apprx 50 g/body. 2. Clinical efficacy was evaluated in the above cases. As a result, an excellent result was obtained in one patient and good efficacies in 9 patients. The efficacy rate was 100% (10/10). Concerning the clinical bacteriological effect, eradication ratio was 83.3% (5/6). Concerning the bacteriological effect against 11 strains of clinical isolates, 4 strains were eradicated, 6 strains were replaced and one strain was unchanged. 3. Neither subjective/objective side effects nor abnormal laboratory test results were observed upon administration of TA.Z/PIPC. These results suggested the usefulness of tazobactam/piperacillin in obstetrics and gynecological infections.